Dr. Rosenzweig Discusses the Standard of Care in Amyloidosis

Michael Rosenzweig, MD
Published: Tuesday, May 01, 2018



Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.

Autologous stem cell transplant, the current standard of care, is generally well tolerated by patients who are eligible, says Rosenzweig. For those who are not eligible, Rosenzweig says that a bortezomib (Velcade)-based regimen is often used, which is also generally well tolerated.

The treatment landscape of immunoglobulin light chain (AL) amyloidosis is rapidly expanding with novel systemic therapies such as daratumumab (Darzalex). Daratumumab is very well tolerated, and it is making its way to the frontline setting, says Rosenzweig. Clinical trials are underway exploring daratumumab in combination with bortezomib-based regimens for AL amyloidosis.
SELECTED
LANGUAGE


Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.

Autologous stem cell transplant, the current standard of care, is generally well tolerated by patients who are eligible, says Rosenzweig. For those who are not eligible, Rosenzweig says that a bortezomib (Velcade)-based regimen is often used, which is also generally well tolerated.

The treatment landscape of immunoglobulin light chain (AL) amyloidosis is rapidly expanding with novel systemic therapies such as daratumumab (Darzalex). Daratumumab is very well tolerated, and it is making its way to the frontline setting, says Rosenzweig. Clinical trials are underway exploring daratumumab in combination with bortezomib-based regimens for AL amyloidosis.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication
x